Rothschild & Co Initiates Coverage On Guardant Health with Buy Rating, Announces Price Target of $203

Benzinga Newsdesk www.benzinga.com Neutral 53.5%

Neg 0% Neu 53.5% Pos 0%

Rothschild & Co analyst Jamie Clark initiates coverage on Guardant Health (NASDAQ:GH) with a Buy rating and announces Price Target of $203.